Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kaoru Tsuchiya

Showing results (101-110 of 149) with videos related to

Pageof 15
Sort By:
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 13, 2018
Non-invasive liver fibrosis assessment correlates with collagen and elastic fiber quantity in patients with hepatitis C virus infectionYutaka Yasui, Tokiya Abe, Masayuki Kurosaki, et al.
International Journal of Molecular Sciences|December 30, 2020
<i>Wisteria floribunda</i> Agglutinin-Positive Mac-2 Binding Protein as a Screening Tool for Significant Liver Fibrosis in Health CheckupNobuharu Tamaki, Masayuki Kurosaki, Yuka Takahashi, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 3, 2025
Atezolizumab Plus Bevacizumab for TACE-Unsuitable Intermediate-Stage HCC Beyond Up-To-7 Criteria: Final Analysis of REPLACEMENTKazuomi Ueshima, Kaoru Tsuchiya, Tatsuya Yamashita, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|June 10, 2020
Hepatitis B surface antigen reduction as a result of switching from long-term entecavir administration to tenofovirNobuharu Tamaki, Masayuki Kurosaki, Sakura Kirino, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|August 31, 2023
Switching from entecavir to tenofovir alafenamide for maintaining complete virological response in chronic hepatitis BShun Ishido, Nobuharu Tamaki, Naoki Uchihara, et al.
Internal Medicine (Tokyo, Japan)|October 1, 2023
A Comparison of Alanine Aminotransferase Normalization between Pemafibrate and Bezafibrate in Patients with Nonalcoholic Fatty Liver DiseaseMichiko Yamada-Shimizu, Nobuharu Tamaki, Masayuki Kurosaki, et al.
Plos One|March 10, 2022
Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinomaShun Kaneko, Masayuki Kurosaki, Kaoru Tsuchiya, et al.
Plos One|April 21, 2020
Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinomaSakura Kirino, Kaoru Tsuchiya, Masayuki Kurosaki, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|December 15, 2020
Early radiological response evaluation with response evaluation criteria in solid tumors 1.1 stratifies survival in hepatocellular carcinoma patients treated with lenvatinibShun Kaneko, Kaoru Tsuchiya, Yutaka Yasui, et al.
Cancers|August 30, 2019
Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular CarcinomaHitomi Takada, Masayuki Kurosaki, Kaoru Tsuchiya, et al.
Pageof 15

Showing results (101-110 of 149) with videos related to

Sort By:
Pageof 15
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 13, 2018
Non-invasive liver fibrosis assessment correlates with collagen and elastic fiber quantity in patients with hepatitis C virus infectionYutaka Yasui, Tokiya Abe, Masayuki Kurosaki, et al.
International Journal of Molecular Sciences|December 30, 2020
<i>Wisteria floribunda</i> Agglutinin-Positive Mac-2 Binding Protein as a Screening Tool for Significant Liver Fibrosis in Health CheckupNobuharu Tamaki, Masayuki Kurosaki, Yuka Takahashi, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 3, 2025
Atezolizumab Plus Bevacizumab for TACE-Unsuitable Intermediate-Stage HCC Beyond Up-To-7 Criteria: Final Analysis of REPLACEMENTKazuomi Ueshima, Kaoru Tsuchiya, Tatsuya Yamashita, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|June 10, 2020
Hepatitis B surface antigen reduction as a result of switching from long-term entecavir administration to tenofovirNobuharu Tamaki, Masayuki Kurosaki, Sakura Kirino, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|August 31, 2023
Switching from entecavir to tenofovir alafenamide for maintaining complete virological response in chronic hepatitis BShun Ishido, Nobuharu Tamaki, Naoki Uchihara, et al.
Internal Medicine (Tokyo, Japan)|October 1, 2023
A Comparison of Alanine Aminotransferase Normalization between Pemafibrate and Bezafibrate in Patients with Nonalcoholic Fatty Liver DiseaseMichiko Yamada-Shimizu, Nobuharu Tamaki, Masayuki Kurosaki, et al.
Plos One|March 10, 2022
Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinomaShun Kaneko, Masayuki Kurosaki, Kaoru Tsuchiya, et al.
Plos One|April 21, 2020
Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinomaSakura Kirino, Kaoru Tsuchiya, Masayuki Kurosaki, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|December 15, 2020
Early radiological response evaluation with response evaluation criteria in solid tumors 1.1 stratifies survival in hepatocellular carcinoma patients treated with lenvatinibShun Kaneko, Kaoru Tsuchiya, Yutaka Yasui, et al.
Cancers|August 30, 2019
Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular CarcinomaHitomi Takada, Masayuki Kurosaki, Kaoru Tsuchiya, et al.
Pageof 15